News | Ventricular Assist Devices (VAD) | February 11, 2019

Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System

First FIVAD device using coplanar energy transfer for wireless power implanted in human in Kazakhstan

Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System

February 11, 2019 — Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the first successful implantation of the FIVAD (Fully Implanted Ventricular Assist Device) into a human. An article about the implantation was also published in the Journal for Heart and Lung Transplantation.1

FIVAD is based on technology created by Leviticus Cardio, a medical technology company headquartered in Israel. It uses patented coplanar energy transfer (CET) to wirelessly power the heart pump, also known as a ventricular assist device (VAD). FIVAD incorporates a heart pump produced by Jarvik Heart Inc, an established manufacturer of ventricular assist devices.

Every year, VADs are surgically implanted into thousands of patients with severe heart failure in lieu of heart transplants. VADs need to continuously be connected to a power source, which requires patients to have a wire coming out of their bodies. This not only severely reduces the patients’ quality of life but, in over 20 percent of cases, causes infections which can lead to hospitalization and severe complications.

FIVAD is a fully implanted VAD system, a Jarvik 2000 pump, powered wirelessly using both internal and external components designed by Leviticus Cardi. This allows patients to walk around without any physical impediments for up to 8 hours a day.

After years of development and animal testing, the first implant of FIVAD in a human took place in December at the National Research Center for Cardiac Surgery in Astana. The patient has been discharged from the hospital and is back leading a normal life.

FIVAD is also equipped with a back-up system (Jarvik Heart, Post Auricular driveline connection) which would allow moving to traditional wired power in case the wireless system failed. While the backup was tested during the implant procedure, it has not been needed since that initial implant test.

Among the guests from the medical community participating in the press conference were:

  • Prof. Mandeep Mehra, professor of medicine, Harvard Medical School and editor-in-chief of The Journal of Heart and Lung Transplantation;
  • Prof. Nir Uriel, director, heart failure, transplant and mechanical circulatory support, University of Chicago and the charmian of the Mechanical Circulatory support council at the International Society of Heart Lung Transplantation;
  • Pya Yuriy Vladimirovich, M.D., CEO of National Research Center for Cardiac Surgery and the lead FIVAD surgeon;
  • Prof. Ivan Netuka, chairman of the Department of Cardiovascular Surgery, surgical director of chronic MCS and heart transplantation, Institute for Clinical and Experimental Medicine, Prague, who participated in the FIVAD surgery;
  • Prof. Stephan Schueler - consultant cardiothoracic surgeon at Newcastle upon Tyne Hospitals Trust and renowned cardiothoracic surgeon;
  • Assoc. Prof. Jiri Maly – deputy director/CMO of Institute for Clinical and Experimental Medicine, Prague, who participated in the FIVAD surgery; and
  • Yigal Kassif, M.D., attending cardiac surgeon and chief of cardiac surgery Intensive Care Unit at Sheba Medical Center in Israel.

Maly said, “We were really satisfied how easy it was to position the internal components of Leviticus’ system during surgery. It exceeded our expectations during the operation. Simplicity of surgery has definitely contributed to the patient’s early recovery”

Uriel added, “This is a significant improvement in the quality of life experienced by the patient. The patient has the freedom to go about his daily routine without having to worry about being connected to a power source via a driveline and can forget for a few hours that he is supported by an LVAD. We, the medical community, cardiologists, cardiac surgeons, VAD coordinators and the patients have wanted this for decades.”

For more information: www.leviticus-cardio.com, www.jarvikheart.com

Reference

1. Pya Y., Maly J., Bekbossynova M., et al. First Human Use of a Wireless Coplanar Energy Transfer Coupled with a Continuous-flow Left Ventricular Assist Device. The Journal of Heart and Lung Transplantation, Feb. 4, 2019. 

https://doi.org/10.1016/j.healun.2019.01.1316

 

 

 

Related Content

People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Two Stents Implanted in Democratic Presidential Candidate Bernie Sanders, suffers chest pain
News | Cath Lab | October 02, 2019 | Dave Fornell, Editor
October 2, 2019 — Democratic presidential candidate Sen.
Bypass Surgery and Coronary Stenting Yield Comparable 10-Year Survival
News | Cath Lab | September 25, 2019
Ten-year survival rates are similar for bypass surgery and coronary stenting with drug-eluting stents in randomized...
Complete Revascularization Superior to Culprit Lesion-only Intervention
News | Cath Lab | September 10, 2019
An international randomized trial has shown that complete revascularization reduces major cardiovascular events...
The cath lab staff UH Portage Medical Center.

The cath lab staff UH Portage Medical Center.

Feature | Cath Lab | September 09, 2019 | Anjan Gupta, M.D., FACC, FSCAI
Primary percutaneous coronary intervention (PCI) is the preferred treatment for acute...
FDA Grants Shockwave Medical Breakthrough Status for Coronary Intravascular Lithotripsy
News | Cath Lab | September 03, 2019
Shockwave Medical Inc. has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA)...
Compound Could Help Improve Heart Attack Recovery
News | Cath Lab | August 27, 2019
Imagine there were a drug that you could take soon after a heart attack that could reduce damage by protecting healthy...
New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Overlay Init